The week in pharma: action, reaction and insight – week to February 3, 2023
By Barbara Obstoj-Cardwell. Editor
Last Tuesday, Dutch gene therapy company uniQure announced a licensing deal with US start-up Apic Bio relating to the latter’s APB-102 to expand its pipeline of gene therapies for neurological disorders. In a heavy week for fourth-quarter and full-year financial results, Pfizer reported record-breaking figures, but warned that the covid factor is receding and that means lower sales and earnings from Comirnaty and Paxlovid. Fellow US fellow pharma major Eli Lilly, posted a down turn in revenues, with disappointing sales of obesity drug Mounjaro. Amgen launched its Amjevita in the USA, marking the first biosimilar to AbbVie’ mega-blockbuster Humira in the all-important American market and opening the floodgates to more copies.
uniQure pipeline bolstered with Phase I/II-ready SOD1 ALS GTx
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze